KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a phase 3b, randomized, double-blind, placebo-controlled trial.

Howard L Sofen, Kurt Gebauer, Lynda Spelman, Paul S Yamauchi, Siu-Long Yao, Tushar Nishandar, Iris Kopeloff, Michael Crane, Ranga Gogineni, Mudgal Kothekar, Jerry Bagel

J Am Acad Dermatol 92(4) 816-824

PMID39722400
PMCID-
DOI10.1016/j.jaad.2024.12.018
发表日期2024-12-26
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: In the primary analysis of a phase 3b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe plaque psoriasis affecting the scalp (NCT03897088), tildrakizumab, an anti-interleukin-23 p19 antibody, met the primary efficacy endpoint at week 16. OBJECTIVE: To evaluate maintenance of tildrakizumab efficacy and safety for the treatment of scalp psoriasis from the week 52 full analysis. METHODS: Patients randomized to tildrakizumab continued receiving tildrakizumab 100 mg every 12 weeks; patients randomized to placebo (analyzed separately) switched to tildrakizumab 100 mg at week 16. Efficacy endpoints included Investigator Global Assessment modified 2011 (scalp) score of 0 or 1 with ≥2-grade improvement and ≥90% improvement in Psoriasis Scalp Severity Index score from baseline. Safety was assessed from adverse events. RESULTS: In patients originally randomized to tildrakizumab versus placebo, Investigator Global Assessment modified 2011 (scalp) and ≥90% improvement in Psoriasis Scalp Severity Index score response rates, respectively, improved from 49.4% versus 7.3% and 60.7% versus 4.9% at week 16 to 62.9% versus 56.1% and 65.2% versus 57.3% at week 52; >80% of week 16 responders to tildrakizumab maintained response. No treatment-related serious adverse events occurred. LIMITATIONS: Results were obtained under controlled clinical conditions. CONCLUSION: Efficacy and safety of tildrakizumab for the treatment of scalp psoriasis are sustained long-term.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。